Journal ArticleOPEN ACCESS

Potential SARS-CoV-2 Spike Protein-ACE2 Interface Inhibitors: Repurposing FDA-approved Drugs

  • Kouznetsova V
  • Zhang A
  • Miller M
  • et al.
Journal of Exploratory Research in Pharmacology (2022) 7(1) 17-29
DOI: 10.14218/jerp.2021.00050
N/ACitations
Citations of this article
6Readers
Mendeley users who have this article in their library.

Abstract

Background and objectives: The SARS-CoV-2 virus Spike (S) protein binds to an angiotensin-converting-enzyme 2 receptor (ACE2) on the surface of cells to allow viral DNA entry. Given the plenitude of FDA-approved antiviral drugs, we aimed to screen those that may be repurposed for treating SARS-CoV-2 infections.

Cite

CITATION STYLE

APA

Kouznetsova, V. L., Zhang, A., Miller, M. A., Tatineni, M., Greenberg, J. P., & Tsigelny, I. F. (2022). Potential SARS-CoV-2 Spike Protein-ACE2 Interface Inhibitors: Repurposing FDA-approved Drugs. Journal of Exploratory Research in Pharmacology, 7(1), 17–29. https://doi.org/10.14218/jerp.2021.00050

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free